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Selection, Addiction and Catalysis: Emerging Trends for
the Incorporation of Noncanonical Amino Acids into
Peptides and Proteins in Vivo
Clemens Mayer*[a]
Background: Stop Codon Suppression
The site-selective incorporation of ncAAs into peptides and
proteins in vivo can be achieved through the suppression of a
stop codon by the action of an orthogonal translation system
(OTS, Figure 1A).[1–3] An OTS is comprised of an engineered
aminoacyl tRNA synthetase (aaRS), which loads a ncAA onto its
corresponding tRNA, while none of the OTS components inter-
acts with endogenous amino acids, aaRSs or tRNAs (=orthogo-
nal, Figure 1B).[4] The incorporation of ncAAs by an OTS is ach-
ieved if : 1) protein engineering efforts have changed the cog-
nate substrate preference of the aaRS to a ncAA of choice, and
2) the tRNA features the anticodon sequence (e.g. , CUA) to a
stop codon, for example, UAG (Figure 1A). Charged tRNAs are
then recruited to the ribosome, where in-frame UAG stop
codons in mRNAs are suppressed, resulting in the site-selective
incorporation of a ncAA into the nascent peptide chain. De-
spite typically modest suppression efficiencies and the fact
that not every ncAA is genetically encodable (metabolic stabili-
ty, limited uptake, etc.), this strategy has proven exceptionally
versatile.[3,4] Indeed, more than 150 ncAAs have been success-
fully incorporated into peptides and proteins of interest in a
variety of model organisms. Since its conception more than 15
years ago, stop codon suppression as a strategy has predomi-
nantly been applied for introducing ncAAs with functional
groups that enable site-selective protein modification and/or
elucidating, altering or regulating protein function.[3,5] Howev-
er, more recently, OTSs have also been repurposed for other
tasks. This Concept article will highlight recent developments
for which ncAA incorporation has proven particularly impactful
and is divided into three sections: 1) Selection, 2) Addiction,
and 3) Catalysis.
Selection: ncAAs in Peptide Macrocyclization
Macrocyclic peptides (MPs) are privileged scaffolds for the de-
velopment of chemical probes and therapeutics.[6,7] Combining
a high degree of functional complexity with a restricted con-
formational flexibility make MPs well-suited to achieve tight
binding to notoriously difficult targets, such as biomolecular
interfaces.[8] Moreover, peptide macrocyclization is a straight-
forward means to reduce protease degradation and can facili-
tate cellular uptake.[9] Lastly, peptides are genetically encodable
and lend themselves to massive parallel screening and selec-
tion efforts that allow for identifying tight binders from
randomized populations. As a result, methods to genetically
encode MP libraries are sought after, yet the number of cycliza-
tion strategies—and therefore, the accessible ring geome-
tries—remain limited.[10]
Bioactive MPs found in nature often feature ncAAs and uti-
lize unique functionalities placed in their side chains to pro-
mote macrocyclization.[11] In an effort to mimic such natural
products, the Suga group has led efforts to encode MPs con-
taining a wide variety of ncAAs in vitro.[12] Taking advantage of
well-defined, reconstituted translation systems, in which natu-
ral aaRS/tRNA pairs are replaced with synthetically pre-charged
tRNAs featuring non-standard building blocks,[13] the group
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generated MPs with up to eleven ncAAs in their sequence.[14]
Placing uniquely reactive functional groups in their side chains
facilitated the installation of novel ring geometries that could
be interfaced with traditional mRNA display[15] and allowed for
selection of MP inhibitors against a variety of target pro-
teins.[12]
Performing analogous experiments in vivo is significantly
more challenging, as multiple, chemically distinct ncAAs
cannot reliably be incorporated simultaneously. Moreover, cyc-
lization strategies need to be compatible with the plethora of
reactive groups inside the producing organism. Nevertheless,
in vivo strategies are desirable, as they can be linked to pheno-
typic screens or selection against potential targets in their
native environment.[12,16,17] Efforts toward developing such
strategies have been led by the Fasan group, who began utiliz-
ing ncAAs with unique functionalities to access MPs from ge-
netically encoded, yet purified peptides.[18–21] Guided by these
efforts, the group established a set of criteria a ncAA needs to
fulfill to enable cyclization in vivo.[22] First, suitable ncAAs
should be amenable to incorporation through stop codon sup-
pression, a fact that limits their structures tyrosine and pyrroly-
sine analogues, as OTSs based on aaRSs for these amino acids
are currently most advanced. Moreover, functionalities intro-
duced by ncAAs need to be sufficiently reactive to undergo
cyclization with a nearby canonical amino acid in the same
peptide, but not too reactive to undergo side reactions with
competing molecules in the cellular milieu. With these criteria
in mind the Fasan group identified aromatic ncAAs featuring
either an appropriate nucleophile or leaving group as candi-
dates to promote peptide macrocyclization in vivo (Figure 2A
and B).[22,23]
For example, introducing 3-(2-mercaptoethyl)aminophenyl-
alanine (MeaF, Figure 2C) allowed cyclization in the presence
of a C-terminal GyrA intein.[23] Inteins transiently form thioest-
ers, which are prone to undergo substitution reactions in the
presence of appropriate nucleophiles (Figure 2A). Specifically,
MP formation in the presence of MeaF is a two-step process:
first, a transthioesterification, promoted by the nucleophilic
sulfhydryl group of MeaF (pKa 8.5), yields a thiolactone, which
then undergoes an irreversible S!N acyl transfer to yield the
desired N-alkyl macrolactam (see Flag-cyclo(Strep3) in Fig-
ure 2D for an example of the structure formed). Rather unex-
pected, the latter step was found to be rate-determining in
vivo and MPs (N>4 in Figure 2A) could only be isolated after
extended production times in Escherichia coli (24 hours). Criti-
cally, Fasan and co-workers showed that MPs obtained through
such a biosynthesis can be used in a model selection strategy.
More specifically, based on a previously identified streptavidin
binding peptide motif (HPQ) 480 MeaF-containing MPs variants
were produced in 96-well plates and their binding properties
assessed in parallel. One peptide (Flag-cyclo(Strep3) in Fig-
ure 2D) demonstrated binding to streptavidin (KD=1.1 mm),
providing a proof-of-concept that this methodology is applica-
ble to identify bioactive MPs.
Another ncAA that allowed for peptide macrocyclization in
vivo was O-2-bromomethyltyrosine (O2beY, Figure 2C).[22]
O2beY features a bromine as leaving group, which is readily
displaced by a nearby cysteine residue to yield small to
medium-sized MPs (n=1 to 9 in Figure 2B). Again, the authors
were not only able to demonstrate efficient macrocyclization
in vivo, but also showcased the potential of this approach by
the design and affinity maturation of a MP inhibitor for the
sonic hedgehog/patched interaction.[24] The matured peptide
HL2-m5 (Figure 2D) underwent quantitative macrocyclization
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Figure 1. A) A ncAA is taken up into the cell, where it is charged onto an orthogonal tRNA through the action of an engineered aaRS. Once charged, this
tRNA, which features the complementary sequence of a stop codon (e.g. , CUA), is recruited to the ribosome, where it suppresses an in-frame stop codon
(UAG) located on an mRNA. B) Schematic representation of orthogonality with respect to the OTS. Note that engineered aaRS and tRNA (orange) do not inter-
act (dashed arrows) with the endogenous aaRS/tRNA pairs (blue).
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in vivo and showed a 120-fold increased affinity, when com-
pared to the parent, linear peptide.
Lastly, the Fasan group also demonstrated that O2beY-medi-
ated macrocyclization is compatible with split intein circular li-
gation of peptides and proteins (SICLOPPS), a widely employed
technique to obtain MPs in vivo.[17,25,26] When combined with
SICLOPPS, O2beY incorporation allowed for the biosynthesis of
bicyclic peptides. A proof-of-principle that the resulting bicyclic
peptides are attractive scaffolds for identifying bioactive MPs is
provided by the biosynthesis of bicyclo-Z8C (Figure 2D), which
was based on the streptavidin-binding peptide described
above. Critically, bicyclo-Z8C showed a 2.5-fold lower IC50
value, when compared to a monocyclic variant, which was
attributed to the lower conformational flexibility of bicyclo-
Z8C.[26]
Together, these examples demonstrate that ncAAs are a
promising means to access and identify bioactive MPs with
novel ring geometries. As the presented strategies enable pep-
tide macrocyclization in vivo, they are now readily available for
interfacing with phenotypic screens and selection strategies.
Thus, future efforts will focus on expanding this methodology
to select mono- and bicyclic peptides for biologically relevant
targets. Moreover, the introduction of ncAAs other than MeaF
and O2beY is likely to make other cyclization strategies avail-
able in the near future. Specifically, ncAAs that enable macro-
cyclization strategies with side chains other than cysteines and
transiently formed thioesters are desirable to access “natural
product-like” MPs with new ring geometries.
Addiction: ncAAs in Biocontainment
Synthetic biology aims to deploy genetically modified organ-
isms (GMOs) as common and valued solutions in clinical, indus-
trial and environmental settings.[27] However, such real-world
applications necessitate the development of biocontainment
strategies, reminiscent to those outlined in the 1975 Asilomar
conference for recombinant DNA.[28] Generally, effective bio-
containment strategies must protect against GMO escape
mechanisms, including mutagenic drift, environmental supple-
mentation and horizontal gene transfer.[29]
In principle, constructing GMOs with an alternative genetic
code by introducing a ncAA into an essential gene (Figure 3A)
would advance the barrier between an engineered and a natu-
ral organism, as survival of the former would depend on an
Figure 2. Schematic representations of in vivo peptide macrocyclization strategies based on ncAAs. A) C-terminal inteins transiently form thioesters, which
can undergo irreversible substitution reactions with proximal nucleophiles. B) Conversely, ncAAs equipped with appropriate leaving groups can undergo a
substitution reaction with a nearby cysteine residue. For both strategies, a successful macrocyclization is critically dependent on fine-tuning the reactivity of
the functional group placed in the side chain of the ncAA. C) Structures of the ncAAs that are used to produce MPs in vivo. D) Schematic representation of
MPs discussed in this section of the article. ncAAs are highlighted in red, potential reaction partners in blue and amino acids identified to bind to streptavidin
in pink. FLAG=MDYKDDDDKGSGS.
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exogenously supplied synthetic molecule. Therefore, the result-
ing synthetic auxotrophs could not be rescued by cross-feeding
with complex media and horizontal gene transfer would be
hampered due to the dependence of the GMO on an alterna-
tive genetic code and a matching OTS. However, a synthetic
biocontainment constructed by introducing a stop codon in
an essential gene can easily be breached by reversion of the
introduced nonsense codon or the introduction of a canonical
amino acid instead of the ncAA. In fact, escape frequencies
(EFs) for GMOs with a single UAG codon at a permissive site in
an essential protein are &10@6–10@7,[29] which does not meet
the National Institutes of Health suggested maximum EF of
10@8.[30] Thus, to achieve tighter containment the need for the
synthetic building block has to be reinforced, for example, by
making protein function strictly dependent on the incorpora-
tion of the ncAA (Figure 3A).
Such addiction of protein function to a synthetic amino acid
can be achieved by various means. For example, Church and
co-workers designed synthetic auxotrophs by computationally
redesigning hydrophobic interactions in protein cores to ex-
clusively accommodate 4,4’-biphenylalanine (bipA, Figure 3B,
C).[31] For the genes of adenylate kinase and tyrosyl-tRNA syn-
thetase this redesign resulted in two separate organisms with
low EFs (&10@8). Moreover, engineering a single GMO that
harbored the identified mutations for both genes amplified
the effect and resulted in a synthetic auxotroph for which no
escape variants could be detected (EF <10@12).
Directed evolution provides another means to redesign the
hydrophobic packing of protein cores to make it depend on a
ncAA. Specifically, the Ellington group selected TEM-1 b-lacta-
mase variants, the ability of which to confer carbenicillin resist-
ance was dependent on the introduction of 3-nitrotyrosine
(3nY) or 3-iodotyrosine (3iY, Figure 3B).[32] For a promising engi-
neered variant, TEM-1-B9, phenylalanine was the only canoni-
cal amino acid that could rescue the activity in absence of
these ncAAs. However, codons for phenylalanine (UUU and
UUC) cannot be accessed by a single mutation from UAG, thus
making this reversion unlikely. The group confirmed that this is
an unlikely escape mechanism by culturing E. coli strains,
which harbored TEM-1.B9 and the OTS on a single plasmid,
continuously in liquid or solid media without detecting any
escape variants (EF <10@11). The single plasmid setup is partic-
ularly notable, as it allowed for transformation of other entero-
bacteriae, which all became dependent on 3nY in the presence
of ampicillin and did not escape the containment (EF <10@9).
Another means for making protein function dependent on
the presence of a ncAA involves replacement of a natural
active site residue with a non-standard one. For example, the
Schultz group reported the incorporation of Ne-acetyllysine
(AcK, Figure 3B) into the essential branched chain aminotrans-
ferase (BCAT) of E. coli (Figure 3D).[33] Specifically, replacing a
catalytic lysine with AcK will first produce an inactive BCAT var-
iant, which is then activated upon deacetylation by endoge-
nous acetyltransferases in E. coli. As such, synthetic auxotrophs
can only breach this containment through mutations that
allow for the incorporation of lysine in response to the UAG
nonsense codon. Indeed, the authors identified this mecha-
nism as the common feature in escape mutants (EF >10@8). Se-
Figure 3. A) Schematic representation of a biocontainment strategy, in which a GMO is addicted to a ncAA. An OTS, provided on a plasmid or integrated in
the genome, enables the introduction of a ncAA into an essential protein. One way to ensure low escape frequencies is making the function of an essential
protein dependent on the incorporation of the ncAA (top right). B) Structures of ncAAs that have been employed to create addicted organisms. C) Depend-
ence on a ncAA can be achieved by redesigning (either by computation or directed evolution) the hydrophobic packing of an essential protein. The compu-
tational redesign of the hydrophobic core of TyrS is shown as an example [PBD IDs: 2YXN (top) and 4OUD (bottom)] . D) Replacing a catalytic lysine residue
with AcK in BCAT from E. coli results in an inactive enzyme that undergoes activation by endogenous deacetylases. E) Schematic representation of a live but
replication-incompetent virus. In the viral genome, multiple conserved residues are replaced by UAG stop codons. As a result, the engineered virus can infect
and replicate in a transgenic cell line harboring an OTS. Conversely, it maintains full infectivity for conventional cell lines but cannot replicate, eliciting a
strong immune response in these cells.
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quence analysis of escape variants revealed a point mutation
in the anticodon of an E. coli lysine tRNA (3’-UUU-5’ to 3’-AUU-
5’), which resulted in an anticodon that could suppress UAG
stop codons through G/U wobble pair formation. To counter
this escape mechanism, a barnase gene featuring two in-frame
UAA stop codons in its mRNA was added to the plasmid. Bar-
nase production is lethal and full-length protein will only be
produced in escape variants featuring the mutated lysine tRNA
anticodon (3’-AUU-5’), which is complementary to the in-frame
UAA stop codons. With this conditional kill switch in place
escape mutants effectively committed suicide, which resulted
in a tight biocontainment (EF <10@11).
While making protein function dependent on the presence
of a ncAA is desirable, it requires a certain degree of design or
evolution. An alternative strategy involves the replacement of
conserved residues with a ncAA across multiple essential
genes. This strategy was showcased by the Isaacs group, who
employed multiplex automated genome engineering
(MAGE)[34] to identify a synthetic auxotroph that featured three
TAG sites in the MurG, DnaS and SerS genes, as well as an OTS
decoding p-azidophenylalanine (pAzF, Figure 3B).[35] In the
identified GMO, addiction to pAzF is achieved by the ability of
the ncAA to replace conserved aromatic residues in these
three genes. Similar to the escape mechanism for AcK-depen-
dent organisms mentioned above though, all escape mutants
in this work featured point mutations in the anticodon of one
of the three endogenous tyrosine tRNAs. The identified muta-
tions converted them into suppressor tRNAs, resulting in the
incorporation of tyrosine instead of pAzF in response to UAG
codons. To overcome this mechanism, the Isaacs group deleted
two of the three E. coli tyrosine tRNAs; the remaining one was
therefore essential for tyrosine incorporation in the GMO,
preventing it from accumulating mutations and becoming a
suppressor tRNA. In addition to a stringent biocontainment (EF
<10@12), the authors demonstrated that the resulting synthetic
auxotroph could not be rescued by cross-feeding and that the
alternative genetic code indeed impeded horizontal gene
transfer.[35]
Related to these efforts, introducing multiple stop codons in
the genome of viruses is an emerging strategy to generate live
but replication-incompetent virus (Figure 3E).[36] These can
serve as live-attenuated vaccines, as they retain their full infec-
tivity and elicit a strong immune response. Zhou and co-work-
ers, for example, have recently created a replication-incompe-
tent influenza A virus, in which multiple UAG codons were
introduced at conserved residues throughout the viral ge-
nome.[37] Viruses created by this strategy were highly reproduc-
tive in transgenic cell lines that featured an OTS to decode
UAG codons with Ne-2-azidoethyloxycarbonyllysine (AeocK),
yet did not show any replication in absence of AeocK (EF
<10@11). As anticipated, these engineered influenza A strains
generated a strong immune response against both parental
and antigenically distinct strains. It is conceivable that this
strategy can be applied to a wide variety of viruses and repli-
cation-incompetent viruses could not only be used prophylac-
tically as vaccines, but also in diagnostic and therapeutic appli-
cations.
Overall, the highlighted examples demonstrate that addic-
tion to ncAAs is a promising means to create tight biocontain-
ment for synthetic biology applications.[29] Future efforts are
likely to expand the number of ncAAs that can be used to
create such GMOs and will see their integration into real-world
applications. To avoid the use of an expensive ncAA, it is con-
ceivable that endogenous metabolic pathways could be taken
advantage of in order to shift the addiction to a more cost
effective, yet still exogenously-supplied synthetic precursor of
a ncAA.[38,39]
Catalysis: ncAAs in Designer Enzymes
The enzyme orotidine-5’-phosphate decarboxylase accelerates
its target transformation by a factor of 1017 with respect to the
uncatalyzed reaction and does so by using only canonical
amino acids.[40] However, the scope of enzyme catalysis accessi-
ble by standard amino acids is fundamentally limited by the di-
versity of functional groups present in their side chains. There-
fore, enzymes in nature routinely recruit electrophiles, redox
equivalents, metal ions, transfer agents, etc. , in the form of co-
factors or co-substrates. Similarly, natural side chains in active
sites can undergo posttranslational modifications to install
uniquely reactive functional groups that promote a desired
transformation (for example, converting cysteine to formylgly-
cine in type I sulfatases).[41]
Enzyme design, in part, aims to create proficient protein cat-
alysts with new-to-nature activities.[42,43] In analogy to the natu-
ral strategies described above, the incorporation of ncAAs into
protein scaffolds has emerged as an attractive means to
expand the reaction scope of designer enzymes beyond what
is possible with canonical side chains.[44,45] For example, ncAAs
that feature bioorthogonal handles in their side chains can be
employed for covalent modification with abiological, transition
metal catalysts (an artificial metalloenzyme, Figure 4A).
Amongst others, the Lewis group has reported the creation of
a designer cyclopropanation enzyme by first introducing pAzF
(Figure 4B) into the binding pocket of prolyl oligopeptidase
(POP) and then recruiting a dirhodium catalyst through a
strain-promoted azide–alkyne cycloaddition.[46] Introducing a
bioorthogonal handle (i.e. , the azide in pAzF) for protein modi-
fication is more desirable than other bioconjugation strategies
that rely on natural side chains (for example, cysteines), as the
modification reaction can be carried out in complex mixtures.[5]
This aspect is critical when attempting to evolve artificial met-
alloenzymes, as anchoring strategies are typically not compati-
ble with the complex cellular milieu.[47] Indeed, the Lewis
group has demonstrated the utility of pAzF in the directed
evolution of the BOP-derived cyclopropanases.[48] By perform-
ing the cofactor anchoring reaction in bacterial lysates, the
group was able to screen libraries of BOP-variants that were
generated by random mutagenesis and could successfully
identify more proficient cyclopropanases. Additionally, these
engineered designer enzymes also showed superior reactivity
and selectivity in related N@H, S@H and Si@H insertion reac-
tions.
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Instead of relying on a biorthogonal handle to recruit a syn-
thetic cofactor, the incorporation of metal-chelating ncAAs
that can directly bind metal ions or complexes is another
means to create artificial metalloenzymes (Figure 4C).[49] For
example, the Schultz group installed (2,2’-bipyridin-5-yl)alanine
(bpyA, Figure 4B) into the E. coli catabolite activator protein,
which upon binding of copper or iron ions endowed the pro-
tein with nuclease activity.[50] More recently, the Roelfes group
has expanded this approach by introducing bpyA into the
promiscuous, hydrophobic binding pockets of multidrug resist-
ance regulators (MDRs). Upon binding copper ions, a number
of MDR-based artificial enzymes were created that could
catalyze abiological Friedel–Crafts alkylation[51,52] and hydration
reactions.[53] The high activities and selectivities observed in
these designer enzymes are the result of embedding the
copper ion (through coordination to bpyA) into the MDR bind-
ing pockets, which aides in recruiting hydrophobic substrates.
Incorporating genetically encodable, metal-chelating ncAAs,
such as bpyA, into protein binding pockets is also an attractive
strategy for future directed evolution campaigns. A metal-che-
lating ncAA alleviates the need for a posttranslational synthetic
step to recruit the catalysts species and therefore could facili-
tate artificial metalloenzyme formation in complex media or
even living cells. As a result, this strategy could significantly in-
crease the throughput, when screening for improved designer
enzymes.
In a variation of this theme, the Hilvert and Schultz groups
have replaced histidine with Nd-methyl histidine (NmH) to posi-
tion a heme prosthetic group in myoglobin[54] and an essential
zinc ion an mannose-6-phosphate isomerase.[55] While the
latter resulted in a GMO addicted to NmH (EF <10@11), for the
former the introduction of NmH was shown to subtly alter the
electronic properties of the bound heme. Notably, installing
NmH as axial heme ligand in a previously engineered myoglo-
bin[56] did not only boost the peroxidase activity[57,58] but also
its promiscuous cyclopropanation activity.[59] Moreover, in the
presence of NmH, cyclopropanation reactions could be carried
out in absence of a reducing agent, conditions under which
the parent histidine variant was largely inactive.[56]
Besides recruiting, positioning and fine-tuning of (synthetic)
metal cofactors, the Roelfes group has recently described a
new strategy for enzyme design, in which a ncAA with a
unique functionality is incorporated to act as a catalytic resi-
due (Figure 4E). Specifically, the incorporation of p-aminophe-
nylalanine (pAF) at position 15 in the MDR from Lactococcus
lactis (LmrR), resulted in LmrR_V15pAF, which promoted hydra-
zone and oxime formation reactions.[60] This activity was as-
cribed to the unique ability of the aniline side chain of pAF to
form an iminium ion (covalent catalysis) with an aldehyde sub-
strate, which then undergoes a transimidation reaction in the
presence of appropriate hydrazine or hydroxylamine substrates
(Figure 4E).[61,62] Critically, the inherent catalytic activity of ani-
lines to promote this reaction was boosted by placing pAF in
the hydrophobic pore of LmrR. Taking advantage of both the
unique reactivity of pAF and the ability of LmrR to recruit sub-
strates, LmrR_V15pAF outperformed aniline in solution by a
factor of &560. Lastly, in a follow-up study the authors demon-
strated that the catalytic contribution of the ncAA can be
boosted through consecutive rounds of directed evolution.[63]
A total of four synergistic mutations were identified that, when
combined, increased the turnover frequency (kcat) of the parent
designer enzyme by almost 100-fold and gave rise to variants
that outperformed aniline in solution by more than four orders
of magnitude.
Overall, these examples demonstrate that the incorporation
of ncAAs into protein scaffolds has already begun to signifi-
cantly expand the reaction scope of designer enzymes. In the
future, placing metal-chelating amino acids into protein scaf-
folds will continue to create new and/or improved metal-bind-
ing environments that will give access to new reactivities. For
Figure 4. A) Introducing a ncAA harboring a biorthogonal handle (B) allows for covalent anchoring of artificial metal cofactors featuring the counterpart of
the biological handle (H). A covalent bond is formed (BH) and the cofactor recruited to a protein binding site. B) Structures of ncAAs which have been used
in enzyme design and schematic representation for which strategy they were used to are provided. C) Introducing a metal-chelating ncAA into a protein scaf-
fold results in metalloenzymes by recruiting or positioning natural or synthetic metal cofactors. D) Introducing a ncAA with unique reactivity results in design-
er enzymes that do not need additional modification to become active. E) pAF-containing enzyme variants accelerate hydrazone (X=NH) and oxime (X=O)
formation reaction through population of an iminium ion (=covalent catalysis) with a carbonyl moiety in the substrate.
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the incorporation of ncAAs that directly promote a target
transformation, the creation and directed evolution of LmrR_
V15pAF opens up questions that need to be answered. For
example, is it a general phenomenon that the performance of
organocatalysts, which are versatile yet notoriously slow, is
boosted by placing them in protein scaffolds by ncAA incorpo-
ration?[64,65] And, are the resulting designer enzymes generally
privileged starting points for directed evolution efforts, as it
was demonstrated for LmrR_pAF?[63] Independent of the an-
swers to these questions, designer enzymes will continue to
make use of ncAAs to catalyze new-to-nature transformations.
Future Directions: Orthogonal Ribosomes
With each section closing with a brief outline of future direc-
tions, this section aims to highlight developments that could
impact all areas discussed in this Concept article. As men-
tioned briefly in the Selection part, the simultaneous incorpora-
tion of multiple, chemically distinct ncAAs is typically not effi-
cient.[66] This stems from the fact that adding codons to the ex-
isting genetic code is not straightforward and the number of
codons readily available for recoding is limited. For example,
universal reassignment of more than one nonsense codons is
difficult, due to their native function to signal for termination
of translation. To meet this challenge, the Chin group has
begun to install a parallel genetic code into model organisms,
by making use of orthogonal ribosomes (ORs).[67] In brief, ORs
feature mutations in the 16S ribosomal RNA that enables them
to recognize mRNAs, which are not translated by endogenous
ribosomes.[68] Conversely, ORs do not recognize native mRNAs
and as a result, do not participate in the synthesis of endoge-
nous proteins. Being now not essential for the survival of the
organism, an OR is free to accumulate mutations that alter its
interaction with tRNAs and/or release factors.[69] Such engineer-
ing efforts have allowed for the addition of codons,[70] the se-
lection of new OTS that are specific for ORs,[71] and the efficient
encoding of two ncAAs simultaneously.[70,72] Thus, it is conceiv-
able that applying ORs to the strategies discussed in this arti-
cle could allow for novel peptide macrocyclization strategies,
reinforce synthetic biocontainment, and further expand the
scope of reactions catalyzed by designer enzymes.
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